跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05479240
NCT05479240尚未招募2 期

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer--Randomized, Open, Multicenter Clinical Study

Fujian Cancer Hospital0 个研究点目标入组 94 人开始时间: 2023年9月1日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
尚未招募
入组人数
94
主要终点
Pathological complete response rate
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Aged 18-75, male or female;
  • •Rectal adenocarcinoma confirmed by histopathology;
  • •The lower margin of the tumor as assessed by MRI was below peritoneal reflex-and cT3 was associated with one or more risk factors（cT3c-d，cN1-2；MRF+；EMVI+）;
  • •Patients who are expected to achieve R0 resection;
  • •Can swallow pills normally;
  • •ECOG PS 0-1;
  • •Have not received any previous anti-tumor therapy for rectal cancer, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.;
  • •Surgical treatment is planned after completion of neoadjuvant therapy;
  • •No contraindications;
  • •Fertile female subjects shall have a negative serological pregnancy test within 72 hours prior to the start of trial drug administration and use effective contraceptive methods during the trial and for at least 3 months after the last dose;For male subjects with fertile female partners, effective contraceptive measures should be used during the trial period and for 3 months after the last dose;

排除标准

  • •Have a history of allergy to monoclonal antibody, tirelizumab, capecitabine, oxaliplatin or other platinum drugs;
  • •Have previously received or are currently receiving any of the following treatments:
  • •A) any surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy for the tumor; B) being treated with an immunosuppressive drug or systemic hormone for immunosuppression purposes within 2 weeks prior to initial use of the study drug (dose >10mg/ day of prednisone or equivalent);In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticosteroid replacement at doses >10mg/ d of prednisone or equivalent are permitted; C) received live attenuated vaccine within 4 weeks prior to initial use of the study drug; D) major surgery or severe trauma within 4 weeks prior to first use of the study drug;
  • •Have any active autoimmune disease or history of autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (may be considered after hormone replacement therapy);Patients with complete remission of psoriasis or childhood asthma/allergy who do not require any intervention as adults may be considered for inclusion, but patients requiring medical intervention with bronchodilators may not be included;
  • •A history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation or allogeneic bone marrow transplantation;
  • •There is not a good control of the heart of the clinical symptoms or disease, including but not limited to: such as (1) the NYHA class II or above for heart failure, (2) the unstable angina, myocardial infarction occurred within 1 year (3), (4) have clinical significance on the chamber of sex or ventricular arrhythmias without clinical intervention or poorly controlled clinical intervention;
  • •Severe infection (CTCAE > level 2) occurred within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, and complications of infection requiring hospitalization;Baseline chest imaging suggests active lung inflammation, signs and symptoms of infection within 14 days prior to initial use of the study drug, or requiring oral or intravenous antibiotic treatment, except for prophylactic use of antibiotics;
  • •Those who were found to have active pulmonary tuberculosis infection through medical history or CT examination, or had active pulmonary tuberculosis infection history within 1 year before enrollment, or had active pulmonary tuberculosis infection history more than 1 year ago but without formal treatment;
  • •Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (hepatitis C antibody positive and HCV RNA higher than the detection limit of analysis method);
  • •Other malignancies diagnosed within 5 years prior to the first use of the study drug, unless malignancies with a low risk of metastasis or death (5-year survival >90%), such as adequately treated basal cell carcinoma of the skin or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, may be considered for inclusion;
  • •Pregnant or lactating women;
  • •In the investigator's judgment, there are other factors that may lead to forced termination of the study, such as other serious medical conditions (including mental illness) requiring concurrent treatment, alcoholism, drug abuse, family or social factors, and factors that may affect the safety or compliance of the subjects.

研究组 & 干预措施

short-range radiotherapy sequential Tislelizumab combined with chemotherapy

Experimental

干预措施: Tislelizumab (Drug)

short-range radiotherapy sequential Tislelizumab combined with chemotherapy

Experimental

干预措施: Capecitabine (Drug)

short-range radiotherapy sequential Tislelizumab combined with chemotherapy

Experimental

干预措施: oxaliplatin (Drug)

short-range radiotherapy sequential Tislelizumab combined with chemotherapy

Experimental

干预措施: short-range radiotherapy (Radiation)

short-range radiotherapy combined with chemotherapy

Experimental

干预措施: Capecitabine (Drug)

short-range radiotherapy combined with chemotherapy

Experimental

干预措施: oxaliplatin (Drug)

short-range radiotherapy combined with chemotherapy

Experimental

干预措施: short-range radiotherapy (Radiation)

结局指标

主要结局

Pathological complete response rate

时间窗: 4 weeks after surgery

Pathological examination of resected tissue samples revealed no residual tumor cells.

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

相似试验

招募中
2 期
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.Advanced Esophageal Squamous Cell Cancer
NCT05323890Shandong Cancer Hospital and Institute15
招募中
2 期
Adjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk endometrial cancerEndometrial CancerCancer - Womb (Uterine or endometrial cancer)
ACTRN12621000273886The University of Sydney135
招募中
2 期
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical CancerCervical Cancer
NCT05511623First Affiliated Hospital of Guangxi Medical University112
进行中（未招募）
2 期
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon CancerColonic NeoplasmsNeoadjuvant TherapyImmune Checkpoint Inhibitors
NCT06124378First Affiliated Hospital of Guangxi Medical University60
招募中
4 期
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung CancerNon-small-cell Lung Cancer (NSCLC)
NCT06357598The Affiliated Hospital of Qingdao University30